Intensity Therapeutics, Inc.

INTS

$4.06

+1.50%

2026-09-03 14:33:33 EDT+$0.06

Healthcare

Biotechnology

NASDAQ

Active Trading

Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid ...

Price Action of INTS

$4.06

+1.50%+$0.06

High—

Low—

52W High-90.7%

Rel. vol—

Interval

Range3.5h

Volume—SMA5SMA10

—

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a small clinical-stage biotechnology company focused on developing therapies for solid tumor cancers, aiming to improve how treatments reach and act within tumors. The company’s central platform centers on an intratumoral delivery concept—creating drug product formulations intended to help destroy cancer cells in a ...Intensity Therapeutics, Inc. (NASDAQ: INTS) is a small clinical-stage biotechnology company focused on developing therapies for solid tumor cancers, aiming to improve how treatments reach and act within tumors. The company’s central platform centers on an intratumoral delivery concept—creating drug product formulations intended to help destroy cancer cells in a way that supports immune-cell engagement within the tumor microenvironment. This approach is designed to address both visible tumor growth and more difficult, less detectable aspects of cancer such as micro-metastatic disease. The company’s primary experimental compound is INT230-6, which is currently in Phase 2 clinical trials. INT230-6 is being studied for multiple difficult-to-treat solid tumors, including cancers affecting the pancreas, colon, bile duct, and squamous cell tumors, among other tumor types such as sarcoma, breast, and liver cancers. Rather than operating purely as a single-program company, Intensity Therapeutics has formed strategic collaboration efforts to test INT230-6 in combination regimens that align with established immuno-oncology standards. Reported collaborations include work with Merck (Merck Sharpe & Dohme) to evaluate INT230-6 together with Keytruda (pembrolizumab) for advanced pancreatic, colon, squamous cell, and bile duct malignancies. The company also has collaboration activity with Bristol-Myers Squibb to study INT230-6 combined with Yervoy (ipilimumab) in patients with advanced liver, breast, and sarcoma cancers. In addition, Intensity has a research collaboration involving major academic and medical research organizations, including a randomized controlled Phase II neoadjuvant study of INT230-6 for women with early-stage breast cancer. From a “business and cost” perspective, Intensity’s profile is typical of a small biotech in development: limited headcount (reported as ~5 full-time and ~7 total employees) and a focus on funding, clinical execution, and partnered research rather than large-scale manufacturing. The company’s financial metrics provided indicate losses and negative profitability measures consistent with R&D-intensive clinical development, where revenue is typically not yet a primary driver and cash burn/financing needs are material. Key performance indicators in the dataset reflect a development-stage operating posture rather than stable operating cash generation. Leadership is anchored by founder and CEO Lewis H. Bender, who serves as both the company’s strategic and operational leader. As Intensity progresses its Phase 2 program(s), its “next steps” are largely tied to clinical outcomes—such as safety/tolerability, response signals, and potential expansion into additional studies or deeper combination trials through existing and future partnerships. The company operates from Shelton/Shelton-area headquarters in Connecticut and maintains its website at https://www.intensitytherapeutics.com.ExpandCollapse

Founded

2012

Employees

CEO

Lewis H. Bender

Full Name

Intensity Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-116.61%

Market Cap

$0.01B

Current Ratio

5.00

WACC

18.80%

ROIC

-123.98%

Contact Information

https://www.intensitytherapeutics.com

203 221 7381

1 Enterprise Drive, Shelton, CT 06484-4779

Key Metrics of INTS

Snapshot

Latest / TTM · 6 periods

Market Cap

$10.97M

ROCE

-123.8%

EV / EBITDA

-0.16x

-23.7% YoY

FCF Yield

-82.8%

-76.2% YoY

Cash Conversion Cycle

-26306.1d

Current Ratio

5.00

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of INTS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-0.83x

n/a

Debt / Equity

0.01

n/a

Current Ratio

5.00

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of INTS

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.99 · Revenue $0.00 · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.75 · Revenue $0.00 · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-3.47 · Revenue $3.00M · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.58 · Revenue $0.00 · 1 analysts

Recent history

Aug 11, 2026
Q2 FY2026 · Results reported
EPS $-1.11 · Revenue $0.00
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $-0.96 · Revenue $0.00
View filing
Mar 27, 2026
FY2025 · Annual results
EPS $-8.56 · Revenue $0.00
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-1.55 · Revenue $0.00
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-3.25 · Revenue $0.00
View filing
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-5.50 · Revenue $0.00

Financial Statements of INTS

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-11.6M	+28.7%	-23.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-9.2M	+39.3%	-28.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.9%	-80.4%	+0.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	5.92x	+209.1%	+2.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$14.1M	+194.8%	-6.3%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-8.56 vs -7.87	-8.7%	-1.11 vs -0.87	-27.2%
Revenue Surprise	—	—	—	—

Insider Transactions of INTS

Acquisitions (A)

Since Mar 26, 2026

Disposals (D)

Since Mar 26, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 16, 2026	DUBIN THOMAS I H	director	Stock Option (right to buy Common Stock)	A	5,500	$4.90
Jul 16, 2026	Donovan Daniel	director	Stock Option (right to buy Common Stock)	A	5,500	$4.90
Jul 16, 2026	GOLDBERG MARK A	director	Stock Option (right to buy Common Stock)	A	5,500	$4.90
Jul 16, 2026	Leahy Emer	director	Stock Option (right to buy Common Stock)	A	5,500	$4.90
Jul 16, 2026	Wesolowski John M	officer: Principal Accounting Officer	Stock Option (right to buy Common Stock)	A	11,000	$4.90

Earnings Call Transcript of INTS

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good morning and welcome to the Intensity Therapeutics Second Quarter 2026 Financial Results Conference Call. Joining the call today is Lewis H. Bender, Intensity's President and CEO, and Joseph Talamo, Intensity's Chief Financial Officer. Shortly before this call, Intensity issued a press release announcing its second quarter 2026 financial results, which is available under the News & Events section of the company's website. Shortly after this webcast, a replay of this call will also be posted. Before we begin, the company reminds you that comments made by management during this conference call contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Intensity Therapeutics. These statements include, but are not limited to, statements relating to the company's expected future plans, cash runway, development activities, projected milestones, business activities, or results. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties is included in the company's earnings release issued today. For a more complete list and description of risk factors, we encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its Forms 10-K, 10-Q, and 8-Ks. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Tuesday, August 11, 2026. Except as required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements. I will now turn the call over to Mr. Bender, Intensity's President and CEO. Lewis Bender: Thank you, Betsy, and thank you to everyone for joining us this morning. It is my pleasure to provide the latest update of our company's progress in the INVINCIBLE-3 and INVINCIBLE-4 studies, our business development activities, and our plans for the second half of 2026. But first, I will turn the call over to Joe Talamo to discuss our second quarter of 2026 financial results. Joe? Joseph Talamo: Thanks, Lou, and good morning. I am pleased to join you today to present a summary of our second quarter 2026 financial results. Our research and development expenses were $1.8 million for the second quarter of 2026, compared with $1.5 million for the same prior-year period, reflecting an increase of $292,000, or 19%. Clinical trial expenses, which primarily consist of our Phase III INVINCIBLE-3 study costs, were $1.2 million during the second quarter of 2026, compared with $936,000 in the same prior-year period. As previously reported, we initiated plans in April 2026 to resume enrollment in the INVINCIBLE-3 study in a limited number of U.S. sites after pausing new site activations and patient …

Leadership Team of INTS

4 executives

Name	Title	Compensation	Gender	Year Born	Status
Lewis H. Bender	Founder, President, Chief Executive Officer & Chairman of the Board	USD 1,015,344	Male	1959	Active
Joseph Talamo	Chief Financial Officer	USD 576,011	Male	1969	Active
John Wesolowski	Principal Accounting Officer & Controller	USD 329,209	Male	1960	Active
James Ahlers	Executive Vice President of Corporate Finance	USD 75,088	Male	1964	Active

Recent News of INTS

Seeking Alpha8/11/2026Neutral

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

PRNewsWire8/11/2026Neutral

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study Cash and cash equivalents of $9.5 million as of June 30, 2026 Increased business development activities Conference call begins at 8:00 a.m. Eastern time today SHELTON, Conn.

PRNewsWire8/4/2026Neutral

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corporate update SHELTON, Conn., Aug. 4, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on August 11, 2026.

PRNewsWire7/15/2026Neutral

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

First patients dosed in Switzerland SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in Switzerland.

PRNewsWire7/1/2026Neutral

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile Strengthened balance sheet supporting disciplined clinical development strategy SHELTON, Conn., July 1, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today provides a mid-year update highlighting the Company's late-stage development programs and growing strategic partnering focus for INT230-6.

Historical Employee Count of INTS

Current

Change

+0.00%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	5	10-K	Mar 27, 2026	View
Dec 31, 2024	5	10-K	Mar 13, 2025	View
Dec 31, 2023	17	10-K	Mar 14, 2024	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Intensity Therapeutics, Inc.